Trial Outcomes & Findings for Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes (NCT NCT03362112)
NCT ID: NCT03362112
Last Updated: 2022-04-14
Results Overview
the plasma lipoprotein-associated phospholipase A2 level of patients
Recruitment status
COMPLETED
Target enrollment
1713 participants
Primary outcome timeframe
Day one
Results posted on
2022-04-14
Participant Flow
Participant milestones
| Measure |
Patients With T2DM
Patients with type 2 diabetes
|
|---|---|
|
Overall Study
STARTED
|
1713
|
|
Overall Study
COMPLETED
|
1622
|
|
Overall Study
NOT COMPLETED
|
91
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Patients With T2DM
n=1713 Participants
Patients with type 2 diabetes
|
|---|---|
|
Age, Continuous
|
58.5 years
STANDARD_DEVIATION 12.5 • n=1713 Participants
|
|
Sex: Female, Male
Female
|
658 Participants
n=1713 Participants
|
|
Sex: Female, Male
Male
|
1055 Participants
n=1713 Participants
|
|
Region of Enrollment
China
|
1713 Participants
n=1713 Participants
|
PRIMARY outcome
Timeframe: Day onethe plasma lipoprotein-associated phospholipase A2 level of patients
Outcome measures
| Measure |
Patients With T2DM
n=1452 Participants
Patients with type 2 diabetes
|
|---|---|
|
Lipoprotein-associated Phospholipase A2
|
238.4 ng/ml
Standard Deviation 111.9
|
SECONDARY outcome
Timeframe: Day onethe glycosylated hemoglobin level of patients
Outcome measures
| Measure |
Patients With T2DM
n=1452 Participants
Patients with type 2 diabetes
|
|---|---|
|
HbA1c
|
9.1 percentage of glycated hemoglobin
Standard Deviation 2.1
|
SECONDARY outcome
Timeframe: Day onelow density lipoprotein cholesterol
Outcome measures
| Measure |
Patients With T2DM
n=1452 Participants
Patients with type 2 diabetes
|
|---|---|
|
LDL-c
|
2.5 mmol/L
Standard Deviation 0.8
|
SECONDARY outcome
Timeframe: Day onethe prevalence of atherosclerosis, diabetic Nephropathy, diabetic retinopathy and diabetic neuropathy
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Day onefast and 120min postprandial C peptide
Outcome measures
Outcome data not reported
Adverse Events
Patients With T2DM
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place